Login
Sangamo Therapeutics NASDAQ: SGMO
Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies
| Name | Sangamo Therapeutics |
| Ticker | SGMO |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Gene Editing - Cell Therapies |
| Price | 10.78 |
| 52W Low/High | 5.05 / 12.48 |
| Market cap | 1.5 B |
| 1Y Total Return |
0.09%
Average |
| 1Y Volatility |
71.04%
More Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies
Details
| Ticker | SGMO |
| Name | Sangamo Therapeutics |
| ISIN | US8006771062 |
| CUSIP | 800677106 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Gene Editing - Cell Therapies |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 9/17/20
| Close Price | 10.78 |
| 52W Low/High | 5.05 / 12.48 |
| Market cap | 1.5 B |
| 1Y Total Return |
0.09%
Average |
| 1Y Volatility |
71.04%
More Risk |
| Beta | 1.12 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -91.2% |
| Cash from Op. / Cur. Liabilities | 0.87 |
| Diluted Earnings / Share | -0.82 |
| ROE | - |
| ROIC | -27.0% |
| Price / Revenue | 13.4 |
| Price / Book | 2.9 |
| Price / CF | 18.4 |
| Current Ratio | 7.2 |
| Cur.Liabilities / Tot.Liabilities | 0.2 |
| Financial Leverage | 0.08 |
| in Mils USD |
rolling-year up to June
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
111
|
76
|
59
|
23
|
25
|
49
|
|
| Gross Profit |
111
|
76
|
59
|
23
|
25
|
49
|
|
| R&D |
158
|
133
|
91
|
59
|
71
|
62
|
|
| EBITDA |
-87
|
-99
|
-60
|
-57
|
-70
|
-29
|
|
| Operating Income |
-110
|
-114
|
-67
|
-59
|
-72
|
-30
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
139
|
114
|
97
|
73
|
70
|
70
|
|
| EPS exc. Extra |
-0.82
|
-0.98
|
-0.70
|
-0.81
|
-0.94
|
-0.42
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
895
|
673
|
628
|
283
|
181
|
230
|
|
| Cash, Eq & Invt ShortTerm |
665
|
443
|
539
|
250
|
172
|
214
|
|
| Total Current Assets |
679
|
462
|
550
|
256
|
176
|
221
|
|
| Total Non-Current Assets |
215
|
212
|
78
|
27
|
5
|
9
|
|
| Intangibles |
93
|
94
|
2
|
2
|
2
|
2
|
|
| Total Liabilities |
383
|
228
|
240
|
89
|
21
|
30
|
|
| Total Current Liabilities |
94
|
82
|
76
|
42
|
14
|
21
|
|
| Long Term Debt |
290
|
146
|
164
|
47
|
6
|
9
|
|
| Shareholder equity |
511
|
445
|
388
|
194
|
160
|
200
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
81
|
-152
|
72
|
14
|
-60
|
-19
|
|
| Depreciation |
14
|
5
|
2
|
1
|
1
|
1
|
|
| Cash from Investing |
69
|
118
|
-323
|
-40
|
47
|
-74
|
|
| Capex |
18
|
47
|
7
|
3
|
2
|
2
|
|
| Cash from Financing |
146
|
143
|
244
|
83
|
15
|
4
|
|
| Stock Issued |
147
|
143
|
245
|
83
|
3
|
9
|
|
| Debt (LT) Issued |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Free Cash Flow |
-19
|
57
|
-342
|
-54
|
-15
|
-137
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
7.2
|
5.6
|
7.2
|
6.1
|
12.2
|
10.5
|
|
| Financial Leverage D/E |
0.08
|
0.09
|
0.00
|
0.00
|
0.00
|
0.00
|
|
| Return on Capital Avg |
-27.0%
|
-22.8%
|
-18.8%
|
-35.5%
|
-33.8%
|
-17.6%
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available